CLEVELAND, April 16, 2020 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced the appointment of B. Kristine Johnson to its Board of Directors
effective April 14, 2020.
Ms. Johnson brings a wealth of health care and medical
technology knowledge, as well as broad experience in finance and
corporate governance. She is currently President and General
Manager of Affinity Capital Management, a venture capital firm that
invests primarily in seed and early-stage health care companies in
the United States, a position she
has held since 2000. Ms. Johnson also currently serves on the Board
of Directors for AtriCure and
ClearPoint Neuro, Inc., both
medical technology companies.
Ms. Johnson held several leadership roles at Medtronic over the course of 17 years,
serving most recently as Senior Vice President and Chief
Administrative Officer. Her experience at Medtronic included
President and General Manager of its vascular business and
President and General Manager of its tachyarrhythmia management
business, among other roles.
Ms. Johnson previously served on the Board of Directors of The
Spectranetics Corporation, a medical device company which was
acquired by Royal Philips, ADC
Telecommunications, which was acquired by Tyco Electronics, and
Pentair, an industrial manufacturing company. She also served as a
member of the Board of Directors of Piper
Sandler (formerly Piper
Jaffray), an investment banking firm, from 2003 to 2019. She
was Lead Director for Piper Sandler
from 2012 to 2018. Ms. Johnson is also currently Chair of the
Investment Advisory Board of the University of
Minnesota Foundation and serves on the boards of several
private entities. She received her B.A. from St. Olaf College.
"ViewRay is an innovative leader making a profound impact on the
lives of cancer patients around the world," said B. Kristine Johnson. "I look forward to working
with the ViewRay board and management team to expand MRIdian's
treatment offerings to even more patients, physicians, and health
systems globally."
ViewRay also announced that Dr. James
Dempsey is retiring from its Board of Directors effective
April 13, 2020. He will continue to
serve in his role as Chief Science Officer for the Company. "We
have filled a deep bench on the Board of Directors to help
transition our innovative technology company into its next phase. I
have served on the board since 2008 and am looking forward to
protecting and extending our innovation lead," said Dr.
Dempsey.
"I wish to thank Dr. Dempsey for his service on the Board of
Directors for the last twelve years. Innovation is the hallmark of
this company, and we are pleased to have Dr. Dempsey dedicated
solely to his critical role as Chief Scientific Officer. We are
also delighted to welcome Ms. Johnson to the board. We look forward
to leveraging her deep expertise in the medical technology space
and believe that her dynamic experience will help strengthen our
position as the leader in MR-guided therapy," said Dan Moore, Chairman of the Board of ViewRay.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures, and
markets the MRIdian® radiation therapy system. MRIdian is built
upon a proprietary high-definition MR imaging system designed from
the ground up to address the unique challenges and clinical
workflow for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purposely
built to deliver high-precision radiation without unnecessary beam
distortion, and consequently, help to mitigate skin toxicity and
other safety concerns that may otherwise arise when high magnetic
fields interact with radiation beams.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2020 and ViewRay's conference calls to discuss its fourth
quarter 2019 and year to date results. Actual results could differ
from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the ability
to commercialize MRIdian Linac System, demand for ViewRay's
products, the ability to convert backlog into revenue, the timing
of delivery of ViewRay's products, the timing, length and severity
of the recent COVID-19 (coronavirus) pandemic, including its
impacts across our businesses on demand, operations and our global
supply chains, the results and other uncertainties associated with
clinical trials, the ability to raise the additional funding needed
to continue to pursue ViewRay's business and product development
plans, the inherent uncertainties associated with developing new
products or technologies, competition in the industry in which
ViewRay operates, and overall market conditions. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to ViewRay's business in
general, see ViewRay's current and future reports filed with the
Securities and Exchange Commission, including its Annual Report on
Form 10-K for the fiscal year ended December
31, 2019 and its Quarterly Reports on Form 10-Q, as updated
periodically with the company's other filings with the SEC. These
forward-looking statements are made as of the date of this press
release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-appointment-of-b-kristine-johnson-to-its-board-of-directors-301042313.html
SOURCE ViewRay, Inc.